Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

28.27USD
20 Sep 2017
Change (% chg)

$0.35 (+1.25%)
Prev Close
$27.92
Open
$27.90
Day's High
$28.65
Day's Low
$27.83
Volume
3,128,940
Avg. Vol
3,971,476
52-wk High
$29.50
52-wk Low
$10.04

Select another date:

Mon, Sep 11 2017

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

BRIEF-Exelixis submits U.S. Supplemental New Drug Application for Cabometyx for the treatment of advanced kidney cancer

* Exelixis submits U.S. Supplemental new drug application for Cabometyx (cabozantinib) for the treatment of previously untreated advanced kidney cancer Source text for Eikon: Further company coverage:

BRIEF-Exelixis announces settlement of dispute with Genentech

* Exelixis announces settlement of dispute with Genentech regarding companies’ collaboration agreement for Cobimetinib

BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial

* Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma

BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib

* IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN

* Exelixis announces independent radiology committee review confirms results from cabosun, the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

BRIEF-Exelixis announces initiation of early-stage trial of combination drug

* Exelixis Inc announces initiation of Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors Source text for Eikon: Further company coverage:

BRIEF-Exelixis Q1 earnings per share $0.05

* Exelixis announces first quarter 2017 financial results and provides corporate update

BRIEF-Exelixis further reduces indebtedness by repaying Silicon Valley Bank term loan

* Exelixis further reduces indebtedness by repaying silicon valley bank term loan

Select another date: